A New View Of Liquid Biopsy
Stroma Liquid Biopsy - The Next Wave Of Proteomic Profiles For Cancer Biomarkers
While
the landscape of cancer-associated DNA mutations has supported the
initial concepts for liquid biopsy, it is now overwhelmingly apparent
that throughout cancer progression, there are necessary adaptive
microenvironments to support metastatic disease. We now present
evidence that some of the essential interactions between stroma and
proliferating cells can in part, be monitored through the protein
response that tracks into the vascularized tumor and re-proportions
the extracellular proteins (serum) found in the general blood
circulation. These proteomic patterns can now be reported as a Stroma
Liquid Biopsy™ which we are launching as a business unit called
Rakta.
Our commercial goal is to associate this knowledge and data to establish relationships with client supplied samples characterized for progressive disease or response to therapies, ultimately achieving biomarkers useful in the clinic. We achieve these goals through partnerships and collaborations in the oncology field, but the discovery patterns can be applied to other disease pathologies.
|
Seed & Soil
- Heterogeneous nature of cancer’s DNA
- Characterize the stroma
- Analyze tumor-associated microenvironment
- Genomic and proteomic evidence
Learn more
No More Needle In The Haystack
- Stroma and proliferating cell interaction
- Monitor biomarker proteins
- Highly observable measurements
Learn more
IP Supports Many New Cancer Management Strategies
- Coagulation
- Complement
- Acute-phase Inflammation
Learn more
IP Supports Proteome Dysregulation In Cancer
- Rakta Protein Panel
- LC-MS Reporting Features
Learn more
New Cancer Targets
- Inflammatory Response
- Regulating factors
Learn more
IP Scope Is Vast
- Triangle of Dysregulation
- Personalized Medicine
Learn more
The Proteogenomic Goal
- Characterize protease inhibitors
- SERPIN inhibitors
Learn more
SERPIN Dysregulation in Cancer
- Active & inactive SERPIN sub-populations
- Partnerships and collaborations, SERPINs and cancer.
Learn more
|
|
|
|
1.Poster Reprint First Presented at New Jersey Cancer Retreat, May 25, 2017.
Haiyan Zheng(1), Swapan Roy(2), Amenah Soherwardy(1), Seema Rahman(2), Matthew Kuruc(2); (1)Rutgers Center for Integrative Proteomics, Piscataway, NJ; (2)Biotech Support Group LLC, Monmouth Junction, NJ; entitled
"Stroma Liquid Biopsy - Proteomic Profiles for Cancer Biomarkers" . Cell. 2011;144:646-674.
2.Zheng
H, Zhao C, Roy S, et al. The
Comparison of the Serum Proteome in Individuals with Cancers versus
those without Cancer, and its application to Wellness. Poster
reprint from 12th Annual US HUPO 2016 Conference, held March 13 –
16, 2016 Boston, MA, USA.
3.Zheng
H, Zhao C, Roy S, et al. The
Commonality of the Cancer Serum Proteome Phenotype as analyzed by
LC-MS/MS, and Its Application to Monitor Dysregulated Wellness.
Poster reprint from AACR Annual Meeting 2016 Conference, held April
17-20, 2016 New Orleans, LA USA
For Detailed Liquid Biopsy Whitepaper
|
|
|
